Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and ...

Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis.

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...

Thomas also held leadership posts with Novartis, Bristol-Myers Squibb ... In addition to developing WU-CART-007, a drug ...

Schrödinger (NASDAQ:SDGR) shares traded higher on Tuesday despite reporting lower-than-expected Q3 2024 financials after the ...

The companies also have an expanded three-year software agreement that will increase access for Novartis to Schrödinger’s ...

The Molecular Glue Drug Development Summit returns to Boston with fresh insights and opportunities! With powerhouse ...

Analyst Brendan Smith from TD Cowen maintained a Buy rating on Schrodinger (SDGR – Research Report) and keeping the price target at ...

Doctors have been fairly quick to jump on the biologics train: According to Spherix, 96% of dermatologists reported using ...

SEC recommends marketing approval for Dr Reddy's SPMS drug Siponimod tablets: Gireesh Babu, New Delhi Friday, November 8, 2024, 08:00 Hrs [IST] The Subject Expert Committee (SEC), ...

He also oversaw U.S. manufacturing operations at Novartis, scaling production and supporting regulatory ... and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st ...